$3.5M gene therapy for hemophilia gets FDA approval | NASCAR & Racing News

- Advertisement -

WASHINGTON (AP) — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.

The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the genetic disorder which primarily affects men. Currently, patients receive frequent, expensive IVs of a protein that helps blood clot and prevent bleeding.

Get more from the Citrus County Chronicle

Prep Zone

Get updates and player profiles ahead of Friday’s high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week



Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Source link

- Advertisement -

Related Articles

Latest Articles